OverviewSuggest Edit

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company which develops and commercializes products in the therapeutic areas of allergy and respiratory disease. The Company's specialty pharmaceutical product candidates comprise pre-filled syringe for use in the emergency treatment of acute allergic reactions, and inhaler products for the treatment of bronchospasm, asthma and chronic obstructive pulmonary disease. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients.

TypePublic
Founded2006
HQSan Diego, US
Websiteadamispharmaceuticals.com

Latest Updates

Employees (est.) (Dec 2018)152(+41%)
Revenue (FY, 2018)$15.1 M(+16%)
Share Price (Jun 2019)$1.5 (+8%)

Key People/Management at Adamis Pharmaceuticals

Dennis J. Carlo

Dennis J. Carlo

CEO
Robert O. Hopkins

Robert O. Hopkins

CFO
Ronald Moss

Ronald Moss

CMO
Thomas Moll

Thomas Moll

VP of Research
David Marguglio

David Marguglio

SVP of Corporate Development
Show more

Adamis Pharmaceuticals Office Locations

Adamis Pharmaceuticals has an office in San Diego
San Diego, US (HQ)
11682 El Camino Real #300
Show all (1)

Adamis Pharmaceuticals Financials and Metrics

Adamis Pharmaceuticals Revenue

Adamis Pharmaceuticals's revenue was reported to be $15.09 m in FY, 2018
USD

Revenue (Q2, 2019)

5.8m

Gross profit (Q2, 2019)

2.1m

Gross profit margin (Q2, 2019), %

36.4%

Net income (Q2, 2019)

(7.7m)

EBIT (Q2, 2019)

(7.7m)

Market capitalization (10-Jun-2019)

68.8m

Closing stock price (10-Jun-2019)

1.5

Cash (30-Jun-2019)

4.1m
Adamis Pharmaceuticals's current market capitalization is $68.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

6.5m13.1m15.1m

Cost of goods sold

4.9m7.4m9.8m

Gross profit

1.6m5.7m5.3m

Gross profit Margin, %

25%43%35%
Quarterly
USDQ2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

1.9m2.1m3.0m3.8m3.4m3.2m3.9m3.8m4.9m5.8m

Cost of goods sold

1.3m1.8m1.7m1.9m2.1m2.1m2.4m2.3m3.6m3.7m

Gross profit

582.1k254.5k1.4m1.9m1.3m1.1m1.5m1.5m1.3m2.1m

Gross profit Margin, %

30%12%45%51%38%35%39%40%26%36%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

5.4m4.1m4.1m17.3m19.3m

Accounts Receivable

805.4k830.1k1.2m

Inventories

14.5k71.0k942.1k1.8m3.3m

Current Assets

4.2m21.5m25.8m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

119.6k4.7m2.1m5.9m11.2m8.5m6.3m4.4m417.1k7.8m399.5k10.7m23.3m9.1m3.4m32.0m9.2m4.1m

Accounts Receivable

744.7k595.6k1.2m1.2m1.0m980.8k1.2m1.2m1.8m2.9m

Inventories

1.2m1.1m914.2k950.0k996.1k2.3m2.6m3.2m3.4m2.9m

Current Assets

2.2m6.0m11.3m8.5m6.4m5.0m2.6m10.7m26.5m13.9m8.7m37.7m17.5m12.0m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Depreciation and Amortization

990.3k2.5m3.1m3.1m

Inventories

14.5k(165.0k)1.9k(882.5k)(5.0m)

Accounts Payable

(1.8m)(289.2k)(1.7m)587.2k846.1k

Cash From Operating Activities

5.4m306.0k
Quarterly
USDQ1, 2015Q2, 2015Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Depreciation and Amortization

495.1k247.6k966.6k1.8m782.6k1.6m2.3m770.9k1.5m2.3m791.9k1.5m

Inventories

(282.1k)(112.9k)27.9k(7.9k)(54.0k)(514.7k)(785.3k)(1.4m)(808.2k)(175.2k)

Accounts Payable

547.7k750.0k977.2k(289.0k)408.8k1.0m316.7k(2.1m)562.9k(256.5k)(400.3k)(1.1m)1.2m603.1k(66.3k)369.6k

Purchases of PP&E

(16.8k)(16.8k)(48.0k)(615.5k)(1.5m)(201.1k)(1.3m)(3.2m)(1.7m)(2.2m)
USDY, 2019

Financial Leverage

1.4 x
Show all financial metrics

Adamis Pharmaceuticals Online and Social Media Presence

Embed Graph

Adamis Pharmaceuticals News and Updates

Adamis Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the second quarter ended June 30, 2019 and provided a business update.

Adamis Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update

SAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the first quarter ended March 31, 2019 and provided a business update.

Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update

SAN DIEGO, March 15, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2018 and provided a business update.

Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Naloxone Pre-Filled Syringe

SAN DIEGO, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its naloxone pre-filled single dose syringe (PFS) product candidate. This injection is designed…

Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Tadalafil Sublingual Tablet

SAN DIEGO, Dec. 28, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its fast-dissolving sublingual tadalafil tablet.  This product candidate is designed for …

Adamis Pharmaceuticals Provides Update on the U.S. Launch of SYMJEPI

SAN DIEGO, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a business update announcing the U.S. launch of FDA-approved SYMJEPI ™ (epinephrine) 0.3mg Injection is planned for early Q1 2019.
Show more

Adamis Pharmaceuticals Blogs

Adamis Pharmaceuticals Provides Launch and Marketing Update for SYMJEPI

SAN DIEGO , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided a progress report and marketing update on the U.S. launch of SYMJEPI TM  (epinephrine) 0.3 mg and 0.15 mg Injections. During this back-to-school season, there is a heightened awareness of

Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors

SAN DIEGO , Aug. 26, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Howard C. Birndorf and Roshawn Blunt to its Board of Directors. Dr. Dennis J. Carlo , President and CEO of Adamis, stated, “We are very excited to bring on these two

Adamis Pharmaceuticals Strengthens Patent Portfolio for its U.S. Compounding Subsidiary

SAN DIEGO , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application (U.S. Patent Application No.

Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update

SAN DIEGO , Aug. 05, 2019 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”), a specialty biopharmaceutical company primarily focused on developing and commercializing products in the therapeutic areas of allergy, respiratory disease and opioid overdose, announced

Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants

Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants Content Import Thu, 08/01/2019 - 09:01 Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Warrants Aug 01, 2019 This release is a backfill fr…

Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants

Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants Content Import Wed, 07/31/2019 - 16:07 Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants Jul 31, 2019 This release is a backfill from a…
Show more

Adamis Pharmaceuticals Frequently Asked Questions

  • When was Adamis Pharmaceuticals founded?

    Adamis Pharmaceuticals was founded in 2006.

  • Who are Adamis Pharmaceuticals key executives?

    Adamis Pharmaceuticals's key executives are Dennis J. Carlo, Robert O. Hopkins and Ronald Moss.

  • How many employees does Adamis Pharmaceuticals have?

    Adamis Pharmaceuticals has 152 employees.

  • What is Adamis Pharmaceuticals revenue?

    Latest Adamis Pharmaceuticals annual revenue is $15.1 m.

  • What is Adamis Pharmaceuticals revenue per employee?

    Latest Adamis Pharmaceuticals revenue per employee is $99.3 k.

  • Who are Adamis Pharmaceuticals competitors?

    Competitors of Adamis Pharmaceuticals include Acticor Biotech, Melinta Therapeutics and CTI BioPharma.

  • Where is Adamis Pharmaceuticals headquarters?

    Adamis Pharmaceuticals headquarters is located at 11682 El Camino Real #300, San Diego.

  • Where are Adamis Pharmaceuticals offices?

    Adamis Pharmaceuticals has an office in San Diego.

  • How many offices does Adamis Pharmaceuticals have?

    Adamis Pharmaceuticals has 1 office.